Skip to main content
Affluent Medical logo

Affluent Medical — Investor Relations & Filings

Ticker · AFME ISIN · FR0013333077 LEI · 969500N30CO4B5N2GN67 PA Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country FR France
Listing PA AFME

About Affluent Medical

https://www.affluentmedical.com

Affluent Medical is a clinical-stage medical technology company that develops innovative, minimally invasive implants designed to restore essential physiological functions. The company's activities are concentrated in two primary therapeutic areas: structural heart disease and urology. It specifically addresses severe mitral valve insufficiency and urinary incontinence. The product pipeline, currently in clinical development, features three key devices: Kalios™, an adjustable annuloplasty ring for mitral valve repair; Epygon™, a biomimetic mitral valve for replacement procedures; and Artus™, an electronic artificial urinary sphincter for treating urinary incontinence. Affluent Medical's technologies are engineered to be adjustable and biomimetic, allowing for implantation via minimally invasive surgery and adaptation to both the patient's anatomy and the progression of their pathology.

Recent filings

Filing Released Lang Actions
Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 30.04.26.
Regulatory Filings Classification · 85% confidence The document is a press release disclosing the number of shares and total voting rights as of April 30, 2026, in compliance with French Commercial Code L.233-8 and AMF Regulation 223-16. It is a routine regulatory announcement rather than the filing of a full report, earnings release, voting results, or share issue. It does not represent a financial report itself but is a general compliance notification. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-05-20 French
Carvolix : Nombre dactions composant le capital social et nombre total de droits de vote au 30.04.26.
Regulatory Filings Classification · 82% confidence The document is a short regulatory news release under French AMF rules disclosing the total number of shares and voting rights as of 30.04.26. It does not contain financial statements or constitute an interim/annual report; it’s simply a compliance announcement of share and voting rights counts. There is no specific category for “voting rights count” notice, so it falls under the general ‘‘Regulatory Filings’’ category (RNS).
2026-05-20 French
Carvolix Announces Positive Results of the Postmarketing Clinical Program Evaluating the TAVIPILOT AI Software.
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the positive results of a post-marketing clinical program for a medical AI software product, TAVIPILOT, and also mentions the publication of the company's 2025 Universal Registration Document (URD). The text includes clinical study results, commercial launch updates, and a fundraising update. It does not contain detailed financial statements or comprehensive annual report content. The mention of the URD publication is brief and part of a broader press release, not the full report itself. The document is a corporate announcement focusing on clinical and commercial progress and fundraising status, typical of a Capital/Financing Update. It is not an Annual Report, Earnings Release, or Regulatory Filing. Therefore, the best classification is Capital/Financing Update (CAP). The document length (6647 characters) supports it being a detailed announcement rather than a short notice or a full report.
2026-05-04 English
Carvolix annonce des résultats positifs du programme clinique post-commercial évaluant le logiciel TAVIPILOT IA.
Capital/Financing Update Classification · 90% confidence The document is a press release announcing positive clinical results for a medical software product and also mentions the publication of the Document d'Enregistrement Universel (DEU) 2025 and a capital raise update. The DEU is a regulatory filing document similar to a universal registration document, often used in European markets. The document does not contain detailed financial statements or comprehensive financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It also does not contain detailed management discussion or earnings highlights typical of an Earnings Release (ER). The document is primarily an announcement of clinical results and the publication of a regulatory filing (DEU) and a capital raise update. Given the nature of the document as a press release with announcements rather than the full report itself, and the mention of the DEU publication and capital raise, the best fitting category is Capital/Financing Update (CAP). The document is not a full financial report but includes important financing information and regulatory filing announcements related to capital raising. Confidence is high due to clear references to capital raising and DEU publication in a press release format.
2026-05-04 French
Carvolix Announces Positive Results of the Postmarketing Clinical Program Evaluating the TAVIPILOT AI Software.
Regulatory Filings Classification · 95% confidence The document is a regulatory news announcement from Carvolix dated May 4, 2026. It reports positive results from a post-marketing clinical program evaluating the TAVIPILOT AI software and mentions the publication of the 2025 Universal Registration Document (URD). The text includes clinical study results, commercial updates, and a fundraising update. However, the document itself is an announcement summarizing these developments rather than the full Universal Registration Document or detailed financial statements. The document length is 8920 characters, which is relatively short for a full annual or interim report. It also includes a link to a PDF file of the regulatory filing, indicating that the full report is attached or available separately. Therefore, this document is best classified as a Regulatory Filings (RNS) announcement, as it provides regulatory news and updates but does not contain the full detailed report or financial data itself.
2026-05-04 English
Document d'enregistrement universel 2025
Annual Report Classification · 100% confidence The document is titled 'DOCUMENT D’ENREGISTREMENT UNIVERSEL 2025' which translates to 'Universal Registration Document 2025'. It includes the annual financial report and is filed with the AMF (Autorité des marchés financiers), the French financial market regulator, under EU regulation 2017/1129. The document is comprehensive (408 pages) and contains detailed sections such as risk factors, financial situation, management, remuneration, governance, and regulatory environment. It explicitly states it includes the annual financial report and is a formal regulatory filing for the year 2025. This type of document corresponds to an Annual Report, which covers the full company activity and financial performance for the fiscal year. The length and content confirm it is not a mere announcement or a certification but the full report itself. FY 2025
2026-04-30 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.